Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD-L1 IHC by Christina Black | Jul 28, 2022
PD-L1 expression by RNA-sequencing and survival from pembrolizumab in non-small cell lung cancer (NSCLC) by Christina Black | Apr 10, 2022
Tumor Inflammation, Obesity, and Proliferative Status as Biomarkers in Gastroesophageal Adenocarcinoma by Christina Black | Dec 7, 2021
Molecular profiling of metastatic renal cell carcinoma treated with ipilimumab-nivolumab by Christina Black | Nov 19, 2021